Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 260,047 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the transaction, the insider directly owned 1,006,439 shares in the company, valued at $4,539,039.89. The trade was a 20.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Wednesday, September 10th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $4.06 on Wednesday. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $5.51. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The company has a 50 day moving average price of $4.42 and a 200 day moving average price of $3.33. The stock has a market capitalization of $1.11 billion, a P/E ratio of -12.30 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analyst Ratings Changes

TSHA has been the subject of several research reports. Robert W. Baird lifted their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th. JMP Securities set a $8.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Finally, Raymond James Financial began coverage on Taysha Gene Therapies in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $10.30.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently modified their holdings of TSHA. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $40,000. Marex Group plc purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $31,000. Finally, Allegheny Financial Group acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $49,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.